Ehsan Zangene

DORSSAA provides a platform for analyzing stability and solubility alteration data to identify drug-protein interactions and therapeutic targets.

This paper introduces CoPISA, a proteomics workflow that identifies combination-specific protein targets in AML, revealing conjunctional targeting mechanisms beyond classical drug synergy.

CoPISA provides a proteomics dataset profiling protein solubility and stability responses to single and combined drug treatments in AML cell lines, enabling analysis of combinatorial drug effects.

The paper presents a graph-theoretic approach to analyze missing data in nominal datasets, revealing hidden structures by treating missingness as informative signals.

This study evaluates two drug combinations for AML treatment, showing improved efficacy over venetoclax-based therapy in specific mutation profiles.

APSiC identifies novel cancer genes and non-genetic drivers from perturbation screens, revealing context-dependent oncogenic mechanisms and functional roles in specific cancers.